Malignant Paraganglioma of the Urinary Bladder: Immunohistochemical Study of Prognostic Indicators

Endocrine Pathology

Volumn 16, Issue 4, 2005, Pages 363-369

  Kovacs, Kalman ^a,b   Bell, C David ^a   Gardiner, Geoffrey W ^a   Honey, R John ^a   Goguen, Jeannette ^a   Rotondo, Fabio ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b 30 Bond Street ^*  (Canada)

Author keywords

Extra adrenal paraganglioma; Immunohistochemistry; Pathology; Prognosis; Urinary bladder neoplasms

Indexed keywords

VASCULOTROPIN;

ADULT; ARTICLE; BLADDER CANCER; CANCER GROWTH; CASE REPORT; CELL DIVISION; CELL PROLIFERATION; CORRELATION ANALYSIS; ELECTRON MICROSCOPY; HEMATURIA; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METASTASIS; PARAGANGLIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; BLADDER TUMOR; CHEMODECTOMA; METABOLISM; PATHOLOGY;

ADULT; HEMATURIA; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; PARAGANGLIOMA, EXTRA-ADRENAL; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 33646705162     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1385/EP:16:4:363     Document Type: Article

References (33)

1. Sheps SG, Jiang NS, Klee GG, van Heerden JA. Recent developments in the diagnosis and treatment of pheochromocytoma. Mayo Clin Proc 65:88-95, 1990.
2. Thompson LD. Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms. A clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26:551-566, 2002.
3. Cheng L, Leibovich BC, Cheville JC, et al. Paraganglioma of the urinary bladder. Can biologic potential be predicted? Cancer 88:844-852, 2000.
4. Karpman E, Zvara P, Stoppaacher R, Jackson TL, Plante MK. Pheochromocytoma of the urinary bladder: update on new diagnostic modalities plus case report. Ann Urol 34:13-19, 2000.
5. Tischler AS, Komminoth P. Extra-adrenal sympathetic paraganglioma: cervical, intrathoracic and urinary bladder. In. DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. World Health Organization Classification ofTumors. Pathology & Genetics. Tumors of endocrine organs. Lyon: IARC Press, 2004; 165-166.
6. Linnoila RI, Keiser HR, Steinberg SM, Lack EE. Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol 21:1168-1180, 1990.
7. Pommier RF, Vetto JT, Billingsly K, Woltering EA, Brennan MF. Comparison of adrenal and extraadrenal pheochromocytomas. Surgery 114:1160-1166, 1993.
8. Leestma JE, Price EB. Paraganglioma of the urinary bladder. Cancer 28:1063-1073, 1971.
9. Kovacs K, Lloyd R, Horvath E, et al. Silent somatotroph adenomas of the human pituitary. A morphologic study of three cases including immunocytochemistry, electron microscopy, in vitro examination, and in situ hybridization. Am J Pathol 134:345-353, 1989.
10. Kovacs K, Stefaneanu L, Horvath E, et al. Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization. Virchows Arch A Pathol Anat Histopathol 418:439-446, 1991.
11. Zimmerman I, Biron R, MacMahon H. Pheochromocytoma of the urinary bladder. N Engl J Med 249:25-26, 1953.
12. Lloyd RV, Blaivas M, Wilson BS. Distribution of chromogranin and S100 protein in normal and abnormal adrenal medullary tissues. Arch Pathol Lab Med 109:633-635, 1985.
13. Unger P, Hoffman K, Pertsemlidis D, Thung S, Wolfe D, Kaneko M. S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal pheochromocytomas. Arch Pathol Lab Med 115:484-487, 1991.
14. Kimura N, Miura W, Noshiro T, Miura Y, Ookuma T, Nagura H. Ki-67 is an indicator of progression of neuroendocrine tumors. Endocr Pathol 5:223-228, 1994.
15. Lin SR, Lee YJ, Tsai JH. Mutations of the p53 gene in human functional adrenal neoplasms. J Clin Endocrinol Metab 78:483-491, 1994.
16. Dahia PLM, Aguiar RCT, Tsanaclis AM, et al. Molecular and immunohistochemical analysis of p53 in phaeochromocytoma. Br J Canc 72:1211-1213, 1995.
17. Clarke MR, Weyant RJ, Watson CG, Carty SE. Prognostic markers in pheochromocytoma. Hum Pathol 28:522-526, 1998.
18. Yoshimoto T, Naruse M, Zeng Z, et al. The relatively high frequency of p53 gene mutations in multiple and malignant phaeochromocytomas. J Endocrinol 159:247-255, 1998.
19. Nagura S, Katoh R, Kawaoi A, Kobayashi M, Obara T, Omata K. Immunohistochemical estimations of growth activity to predict biological behavior of pheochromocytomas. Mod Pathol 12:1107-1111, 1999.
20. van der Harst E, Bruining HA, Bonjer HJ, et al. Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? J Pathol 191:175-180, 2000.
21. Lam KY, Lo CY, Wat NMS, Luk JM, Lam KSL. The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas. J Clin Pathol 54:443-448, 2001.
22. Kimura N, Watanabe T, Noshiro T, Shizawa S, Miura Y. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol 16:23-32, 2005.
23. Favier J, Plouin PF, Corvol P, Gasc JM. Angiogenesis and vascular architecture in pheochromocytomas. Distinctive traits in malignant tumors. Am J Pathol 161:1235-1246, 2002.
24. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364, 1996.
25. Cheung N, Wang MP, Yuen ST, Leung SY, Chuz LP. Tissue specific expression patterns of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon. Hum Pathol 29:910-914, 1998.
26. Torimura T, Sata M, Uenu T, et al. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 29:986-991, 1998.
27. Sengjev DR, Van de Water L, Brown LF, et al. Vascular permeability factor (VPF, VEGF) and tumor biology. Cancer Metastasis Rev 12:303-324, 1993.
28. Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L. Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 10:229-235, 1999.
29. Dannenberg H, Speel EJM, Zhao J, et al. Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas. Am J Pathol 157:353-359, 2000.
30. Edström E, Mahlamaki E, Nord B, et al. Comparative genomic hybridization reveals frequent losses of chromosomes 1p and 3q in pheochromocytomas and abdominal paragangliomas, suggesting a common genetic etiology. Am J Pathol 156:651-659, 2000.
31. Young AL, Baysal BE, Deb A, Young WF, Jr. Familial malignant catecholamine-secreting paraganglioma with prolonged survival associated with mutation in the succinate dehydrogenase B gene. J Clin Endocrinol Metab 87:4101-4105, 2002.
32. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab 87:4771-4774, 2002.
33. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 63:5615-5621, 2003.